ARCHIVES

Drug Development: FDA Grants Breakthrough Therapy Designation To CTL019 in ALL

This article is from The Cancer Letter archive.

Vol. 40 No. 24 | June 11, 2014

Download PDF Visit The Full Archive

Related Articles

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

January 28, 2011

Compromise on 6,000 Grants Would Make NCI Payline Around 163-164: Natcher Committee Close to Markup

June 28, 1985

Eight CCRU, 20 CCSP Applications Submitted, Quality Is ‘Heartening’

November 19, 1982

NCI Program: DOD’s TRICARE To Cover Patient Costs In NCI Prevention, Early detection Trials

September 10, 1999

Oncology Nursing Society Small Grants Available

July 19, 1996

DCE Board Approves Concept For 14-19 New Grants, Four New Contracts

November 4, 1988